Skip to content
‹ Back to IndustriesSciences

Watch: Disney Donates $1 Million to STEM Following Success of ‘Black Panther’

Disney donated $1 million to STEM programs through the Boys and Girls Clubs of America following the success of 'Black Panther.' The donation is intended to help youth develop high-tech skills inspired by the film's portrayal of advanced technology. The initiative reflects a broader effort to connect pop culture with educational opportunity.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences ·
Share
Watch: Disney Donates $1 Million to STEM Following Success of ‘Black Panther’

Key takeaways

01

Disney committed $1 million to STEM programs at the Boys and Girls Clubs of America after 'Black Panther' resonated strongly with young audiences.

02

The donation aims to equip kids with high-tech skills seen as essential for future career success.

03

The 'Black Panther' film's showcase of advanced technology served as a direct inspiration for the philanthropic initiative.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

STEM (Science, Technology, Engineering, and Math) programs are a part of the Boys and Girls Clubs of America. According to Disney’s press release on Monday, the donation will help kids develop high-tech skills that are essential to helping youth succeed. “It is thrilling to see how inspired young audiences were by the spectacular technology in the film, so it’s fitting that we show our appreciation by helping advance STEM programs for the youth…” – Bob Iger, Disney CEO. As a result of the donation, STEM Centers of Innovation will be built in 12 cities, including Oakland, Philadelphia, and Atlanta. “Thanks to Disney’s support, we can expand our outreach and allow more youth to find their passions and discover STEM careers.” – Jim Clark, President, and CEO of Boys & Girls Clubs of America.

For the latest news, videos, and podcasts in the Science Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates!

Twitter – twitter.com/marketscale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Clinical data harmonization is the bottleneck for life sciences AI

Clinical data harmonization is the bottleneck for life sciences AI

Life sciences companies moving AI from experimentation to scale keep running into messy trial data. One study can draw on EDC, health records, eCOA tools, wearables and imaging, and data teams at pharma SMEs often spend up to 80% of their time wrangling it. Commentators point to lakehouse architectures and data-cleansing AI agents, though the agents are still at proof of concept.

  • 01Treat automation gains as proof-of-concept for now; evaluate AI/harmonization choices based on data readiness, governance, and whether the architecture supports traceability and regulatory needs.

Sep 26, 2026

CDMOs’ new capacity skews stainless by liters, but single-use leads by system count

CDMOs’ new capacity skews stainless by liters, but single-use leads by system count

Contract Pharma reports bioTRAK data projecting CDMOs will install roughly 120 bioreactors by 2030. It says 71% of added volume is large-scale stainless steel, while 61% of systems are single-use.

  • 01Utilization discipline is still driving builds: BioTRAK’s Dawn Ecker told Contract Pharma expansion conversations typically start after a site is booked above ~80% for several years.

Sep 22, 2026

Pharma supplier diversification means little if every supplier uses the same airport

Pharma supplier diversification means little if every supplier uses the same airport

Biocair's Patrick Wohl argues in Pharmaceutical Commerce that life sciences firms must map airports, sea lanes, customs gateways and carriers alongside suppliers. Suppliers spread across countries can still share one air hub. The fix he describes is pre-qualified alternate routes and continuous review, with clinical trial shipments and cold-chain medicines the first cargo exposed when a corridor closes.

  • 01A supplier base spread across several countries can still be a single point of failure if every shipment routes through one airport hub or corridor; the sharper question for a logistics provider is which hubs each qualified lane actually depends on.
  • 02Gartner data cited by MD+DI gives a benchmark: 42% of procurement leaders rank supply disruption as their organization's top risk, with geopolitical issues including tariffs and regulatory changes ranking third.
  • 03A route map ages fast. Pharmaceutical Commerce published the mapping argument on July 24 and was reporting fresh Red Sea and Iran-related freight risk for pharma lanes by Aug. 10, which is the case for treating mapping as a recurring review rather than a project.

Sep 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512